Abstract
The Brown University Child & Adolescent Psychopharmacology UpdateVolume 8, Issue 11 p. 1-8 Table of Contents First published: 25 October 2006 https://doi.org/10.1002/cpu.20031AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Psychopharmacological efficacy profiles: Divalproex for adolescent conduct disorder. Studies show atomoxetine effective, well-tolerated in young ADHD patients. Stimulants for driving performance in teens with ADHD. Oxcarbazepine and cognitive function in youth with partial seizures. Oxcarbazepine for very young children with epilepsy. Results of analysis highlight need for longer-term atomoxetine treatment. Study suggests more pervasive effects of autism. Autism: divalproex for irritability with fluoxetine. Non-medical use of stimulant drugs. Treating postpartum depression. CBT for PANDAS-related OCD. Topiramate for co-occurring bipolar and disruptive behavior disorders. Approval: Generic lamotrigine tablets. Approval: Generic topiramate tablets. Under FDA review: Guanfacine extended-release for ADHD. Volume8, Issue11November 2006Pages 1-8 RelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Brown University Child & Adolescent Psychopharmacology Update
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
